| Year |
Citation |
Score |
| 2018 |
Torres-Collado AX, Jazirehi AR. Overcoming Resistance of Human Non-Hodgkin's Lymphoma to CD19-CAR CTL Therapy by Celecoxib and Histone Deacetylase Inhibitors. Cancers. 10. PMID 29904021 DOI: 10.3390/cancers10060200 |
0.45 |
|
| 2018 |
Torres-Collado AX, Knott J, Jazirehi AR. Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAF-Specific Inhibitor). Cancers. 10. PMID 29795041 DOI: 10.3390/cancers10060157 |
0.326 |
|
| 2017 |
Toress-Collado AX, Nazarian R, Jazirehi AR. Rescue of cell cycle progression in BRAF(V600E) inhibitor-resistant human melanoma by a chromatin modifier. Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine. 39: 1010428317721620. PMID 28936920 DOI: 10.1177/1010428317721620 |
0.356 |
|
| 2016 |
Onea AS, Jazirehi AR. CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas. American Journal of Cancer Research. 6: 403-24. PMID 27186412 |
0.327 |
|
| 2014 |
Jazirehi AR, Nazarian R, Torres-Collado AX, Economou JS. Aberrant apoptotic machinery confers melanoma dual resistance to BRAF(V600E) inhibitor and immune effector cells: immunosensitization by a histone deacetylase inhibitor. American Journal of Clinical and Experimental Immunology. 3: 43-56. PMID 24660121 |
0.309 |
|
| 2014 |
Jazirehi AR, Kurdistani SK, Economou JS. Histone deacetylase inhibitor sensitizes apoptosis-resistant melanomas to cytotoxic human T lymphocytes through regulation of TRAIL/DR5 pathway. Journal of Immunology (Baltimore, Md. : 1950). 192: 3981-9. PMID 24639349 DOI: 10.4049/Jimmunol.1302532 |
0.464 |
|
| 2013 |
Torres-Collado AX, Jazirehi AR. Circumvention of drug-resistance via decitabine-mediated DNMT1 depletion. Epigenomics. 5: 253-54. PMID 24303552 |
0.322 |
|
| 2013 |
Bonavida B, Jazirehi A, Vega MI, Huerta-Yepez S, Baritaki S. Roles Each of Snail, Yin Yang 1 and RKIP in the Regulation of Tumor Cells Chemo-immuno-resistance to Apoptosis. Forum On Immunopathological Diseases and Therapeutics. 4. PMID 24187651 DOI: 10.1615/Forumimmundisther.2013008299 |
0.564 |
|
| 2013 |
Jazirehi AR, Arle D. Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistance. American Journal of Clinical and Experimental Immunology. 2: 55-74. PMID 23885325 |
0.532 |
|
| 2012 |
Quatromoni JG, Wang Y, Vo DD, Morris LF, Jazirehi AR, McBride W, Chatila T, Koya RC, Economou JS. T cell receptor (TCR)-transgenic CD8 lymphocytes rendered insensitive to transforming growth factor beta (TGFβ) signaling mediate superior tumor regression in an animal model of adoptive cell therapy. Journal of Translational Medicine. 10: 127. PMID 22713761 DOI: 10.1186/1479-5876-10-127 |
0.331 |
|
| 2012 |
Jazirehi AR, Economou JS. Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs. Molecular Cancer Therapeutics. 11: 1332-41. PMID 22532603 DOI: 10.1158/1535-7163.MCT-11-0814 |
0.441 |
|
| 2012 |
Jazirehi AR, Wenn PB, Damavand M. Therapeutic implications of targeting the PI3Kinase/AKT/mTOR signaling module in melanoma therapy. American Journal of Cancer Research. 2: 178-91. PMID 22485197 |
0.47 |
|
| 2012 |
Masood A, Shahshahan MA, Jazirehi AR. Novel approaches to modulate apoptosis resistance: basic and clinical implications in the treatment of chronic lymphocytic leukemia (CLL). Current Drug Delivery. 9: 30-40. PMID 22023214 |
0.332 |
|
| 2011 |
Shahshahan MA, Beckley MN, Jazirehi AR. Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects. American Journal of Cancer Research. 1: 913-24. PMID 22016836 |
0.509 |
|
| 2011 |
Jazirehi AR, Bonavida B. Development of rituximab-resistant B-NHL clones: an in vitro model for studying tumor resistance to monoclonal antibody-mediated immunotherapy. Methods in Molecular Biology (Clifton, N.J.). 731: 407-19. PMID 21516425 DOI: 10.1007/978-1-61779-080-5_33 |
0.576 |
|
| 2011 |
Jazirehi AR, Baritaki S, Koya RC, Bonavida B, Economou JS. Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction. Cancer Research. 71: 1406-17. PMID 21159666 DOI: 10.1158/0008-5472.Can-10-1296 |
0.591 |
|
| 2011 |
Vega GG, Vega MI, Huerta-Yepez S, Jazirehi A, Mayani H, Martinez-Maza O, Morrison S, Bonavida B. Cytotoxic Activity of Anti-CD20-hIFN-α on Rituximab-Resistant B-NHL Clones and Synergy with Chemotherapy, Blood. 118: 3499-3499. DOI: 10.1182/Blood.V118.21.3499.3499 |
0.543 |
|
| 2010 |
Baritaki S, Huerta-Yepez S, Sahakyan A, Karagiannides I, Bakirtzi K, Jazirehi A, Bonavida B. Mechanisms of nitric oxide-mediated inhibition of EMT in cancer: inhibition of the metastasis-inducer Snail and induction of the metastasis-suppressor RKIP. Cell Cycle (Georgetown, Tex.). 9: 4931-40. PMID 21150329 DOI: 10.4161/Cc.9.24.14229 |
0.578 |
|
| 2010 |
Jazirehi AR. Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy. Anti-Cancer Drugs. 21: 805-13. PMID 20679890 DOI: 10.1097/CAD.0b013e32833dad91 |
0.412 |
|
| 2010 |
Bonavida B, Huerta-Yepez S, Jazirehi AR, Militello L, Uematsu N, Spandidos DA, Baritaki S, Vega MI. Clinical Significance of the Inhibition of YY1 Activity and Expression by Therapeutic Anti-Cancer Antibodies Forum On Immunopathological Diseases and Therapeutics. 1: 81-95. DOI: 10.1615/Forumimmundisther.V1.I1-2.60 |
0.569 |
|
| 2009 |
Vega MI, Huerta-Yepez S, Martinez-Paniagua M, Martinez-Miguel B, Hernandez-Pando R, González-Bonilla CR, Chinn P, Hanna N, Hariharan K, Jazirehi AR, Bonavida B. Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 6582-94. PMID 19861448 DOI: 10.1158/1078-0432.Ccr-09-1234 |
0.57 |
|
| 2008 |
Vega MI, Martinez-Paniagua M, Jazirehi AR, Huerta-Yepez S, Umezawa K, Martinez-Maza O, Bonavida B. The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs. Leukemia & Lymphoma. 49: 1982-94. PMID 18949621 DOI: 10.1080/10428190802357071 |
0.657 |
|
| 2008 |
Baritaki S, Suzuki E, Umezawa K, Spandidos DA, Berenson J, Daniels TR, Penichet ML, Jazirehi AR, Palladino M, Bonavida B. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. Journal of Immunology (Baltimore, Md. : 1950). 180: 6199-210. PMID 18424742 DOI: 10.4049/Jimmunol.180.9.6199 |
0.703 |
|
| 2008 |
Baritaki S, Rodriguez J, Helguera G, Martinez-Paniagua M, Vega M, Huerta-Yepez S, Jazirehi A, Spandidos D, Penichet ML, Bonavida B. Identification of Differentially Expressed Genes in the Rituximab- Resistant Clone (Ramos RR1) Compared to Wildtype Sensitive Ramos: Therapeutic Implications in Rituximab-Resistance Blood. 112: 3770-3770. DOI: 10.1182/Blood.V112.11.3770.3770 |
0.601 |
|
| 2007 |
Jazirehi AR, Vega MI, Bonavida B. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Research. 67: 1270-81. PMID 17283164 DOI: 10.1158/0008-5472.CAN-06-2184 |
0.652 |
|
| 2005 |
Hongo F, Garban H, Huerta-Yepez S, Vega M, Jazirehi AR, Mizutani Y, Miki T, Bonavida B. Inhibition of the transcription factor Yin Yang 1 activity by S-nitrosation. Biochemical and Biophysical Research Communications. 336: 692-701. PMID 16143308 DOI: 10.1016/J.Bbrc.2005.08.150 |
0.769 |
|
| 2005 |
Vega MI, Huerta-Yepez S, Jazirehi AR, Garban H, Bonavida B. Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis. Oncogene. 24: 8114-27. PMID 16103877 DOI: 10.1038/Sj.Onc.1208954 |
0.802 |
|
| 2005 |
Vega MI, Jazirehi AR, Huerta-Yepez S, Bonavida B. Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively. Journal of Immunology (Baltimore, Md. : 1950). 175: 2174-83. PMID 16081784 DOI: 10.4049/Jimmunol.175.4.2174 |
0.717 |
|
| 2005 |
Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene. 24: 2121-43. PMID 15789036 DOI: 10.1038/Sj.Onc.1208349 |
0.689 |
|
| 2005 |
Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Research. 65: 264-76. PMID 15665303 |
0.641 |
|
| 2005 |
Neshat M, Jazirehi AR, Bonavida B. Chemosensitization of Drug-Resistant Ramos B-NHL to Drug-Induced Apoptosis: YY1 Expression Is Decreased in Response to Cytoskeletal-Interacting Drugs. Blood. 106: 4806-4806. DOI: 10.1182/Blood.V106.11.4806.4806 |
0.624 |
|
| 2005 |
Suzuki E, Jazirehi AR, Bonavida B. Rituximab-Mediated Inhibition of the PI3K-Akt Survival Signaling Pathway in B-NHL Cell Lines Leading to Downregulation of Bclxl Expression and Chemosensitization. Blood. 106: 2830-2830. DOI: 10.1182/Blood.V106.11.2830.2830 |
0.704 |
|
| 2005 |
Suzuki E, Jazirehi A, Palladino M, Bonavida B. Chemosensitization of Drug and Rituximab-Resistant Daudi B-NHL Clones to Drug-Induced Apoptosis by the Proteasome Inhibitor NPI-0052. Blood. 106: 1521-1521. DOI: 10.1182/Blood.V106.11.1521.1521 |
0.732 |
|
| 2005 |
Vega MI, Jazirehi AR, Huerta-Yepez S, Bonavida B. Regulation of Chemoresistance and Immune Resistance of B-NHL Cell Lines by Overexpression of YY1 and Bcl-xL, Respectively: Reversal of Resistance by Rituximab. Blood. 106: 1517-1517. DOI: 10.1182/Blood.V106.11.1517.1517 |
0.734 |
|
| 2005 |
Vega M, Jazirehi A, Bonavida B. Reversal of Rituximab-Resistant AIDS-B-NHL Clone to Chemotherapeutic Drug-Induced Apoptosis by Bortezomib and DHMEQ. Blood. 106: 1516-1516. DOI: 10.1182/Blood.V106.11.1516.1516 |
0.728 |
|
| 2005 |
Jazirehi AR, Bonavida B. Sensitization of Rituximab-Sensitive and Rituximab-Resistant B-NHL Cell Lines/Clones to TRAIL-Induced Apoptosis by Bortezomib and NF-κB Inhibitors. Blood. 106: 1514-1514. DOI: 10.1182/Blood.V106.11.1514.1514 |
0.72 |
|
| 2004 |
Jazirehi AR, Vega MI, Chatterjee D, Goodglick L, Bonavida B. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab. Cancer Research. 64: 7117-26. PMID 15466208 DOI: 10.1158/0008-5472.Can-03-3500 |
0.651 |
|
| 2004 |
Odabaei G, Chatterjee D, Jazirehi AR, Goodglick L, Yeung K, Bonavida B. Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis. Advances in Cancer Research. 91: 169-200. PMID 15327891 DOI: 10.1016/S0065-230X(04)91005-6 |
0.698 |
|
| 2004 |
Vega MI, Huerta-Yepaz S, Garban H, Jazirehi A, Emmanouilides C, Bonavida B. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene. 23: 3530-40. PMID 15077178 DOI: 10.1038/Sj.Onc.1207336 |
0.752 |
|
| 2004 |
Huerta-Yepez S, Vega M, Jazirehi A, Garban H, Hongo F, Cheng G, Bonavida B. Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression. Oncogene. 23: 4993-5003. PMID 15048072 DOI: 10.1038/Sj.Onc.1207655 |
0.79 |
|
| 2004 |
Jazirehi AR, Bonavida B. Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Molecular Cancer Therapeutics. 3: 71-84. PMID 14749477 |
0.679 |
|
| 2004 |
Jazirehi AR, Umezawa K, Bonavida B. Sensitization of Rituximab-Resistant Ramos RR1 and Daudi RR1 Clones to Various Chemotherapeutic Drugs by a Novel Nuclear Factor-κB Activation Inhibitor. Blood. 104: 83-83. DOI: 10.1182/Blood.V104.11.83.83 |
0.696 |
|
| 2004 |
Jazirehi AR, Bonavida B. Cellular and Molecular Characterization of Rituximab-Resistant CD20+ NHL Ramos (Ramos RR1) and Daudi (Daudi RR1) Clones: Development of Cross-Resistance to Cytotoxic Stimuli. Blood. 104: 3410-3410. DOI: 10.1182/Blood.V104.11.3410.3410 |
0.677 |
|
| 2004 |
Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B. Rituximab-Mediated Inhibition of the Constitutive NIK/IKK/IκB/NF-κB Signaling Pathway in Non-Hodgkin’s Lymphoma (NHL) B-Cell Lines: Role in Chemo-Sensitization. Blood. 104: 288-288. DOI: 10.1182/Blood.V104.11.288.288 |
0.702 |
|
| 2004 |
Vega MI, Huerta-Yepez S, Jazirehi AR, Garban H, Bonavida B. Rituximab-Mediated Inhibition of the Transcription Repressor Yin-Yang 1 (YY1) in NHL B Cell Lines: Upregulation of Fas Expression and Sensitization to Fas-Induced Apoptosis. Blood. 104: 287-287. DOI: 10.1182/Blood.V104.11.287.287 |
0.794 |
|
| 2003 |
Jazirehi AR, Gan XH, De Vos S, Emmanouilides C, Bonavida B. Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis. Molecular Cancer Therapeutics. 2: 1183-93. PMID 14617792 |
0.687 |
|
| 2003 |
Hansch C, Jazirehi A, Mekapati SB, Garg R, Bonavida B. QSAR of apoptosis induction in various cancer cells. Bioorganic & Medicinal Chemistry. 11: 3015-9. PMID 12788369 DOI: 10.1016/S0968-0896(03)00184-6 |
0.56 |
|
| 2003 |
Cal C, Garban H, Jazirehi A, Yeh C, Mizutani Y, Bonavida B. Resveratrol and cancer: chemoprevention, apoptosis, and chemo-immunosensitizing activities. Current Medicinal Chemistry. Anti-Cancer Agents. 3: 77-93. PMID 12678904 |
0.758 |
|
| 2003 |
Huerta S, Harris DM, Jazirehi A, Bonavida B, Elashoff D, Livingston EH, Heber D. Gene expression profile of metastatic colon cancer cells resistant to cisplatin-induced apoptosis. International Journal of Oncology. 22: 663-70. PMID 12579322 |
0.611 |
|
| 2003 |
Hansch C, Bonavida B, Jazirehi AR, Cohen JJ, Milliron C, Kurup A. Quantitative structure-activity relationships of phenolic compounds causing apoptosis. Bioorganic & Medicinal Chemistry. 11: 617-20. PMID 12538027 DOI: 10.1016/S0968-0896(02)00326-7 |
0.491 |
|
| 2002 |
Emmanouilides C, Jazirehi AR, Bonavida B. Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine. Cancer Biotherapy & Radiopharmaceuticals. 17: 621-30. PMID 12537665 DOI: 10.1089/108497802320970226 |
0.605 |
|
| 2002 |
Hansch C, Bonavida B, Jazirehi AR, Cohen JJ, Milliron C, Kurup A. Quantitative structure - Activity relationships of phenolic compounds causing apoptosis Bioorganic and Medicinal Chemistry. 11: 617-620. DOI: 10.1016/S0968-0896(02)00326-7 |
0.455 |
|
| 2001 |
Jazirehi AR, Ng CP, Gan XH, Schiller G, Bonavida B. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 7: 3874-83. PMID 11751478 |
0.799 |
|
| 1999 |
Bonavida B, Ng CP, Jazirehi A, Schiller G, Mizutani Y. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics (review). International Journal of Oncology. 15: 793-802. PMID 10493964 DOI: 10.3892/Ijo.15.4.793 |
0.779 |
|
| Show low-probability matches. |